Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote & News

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 442 287 8990

Website: www.lineagecell.com

Address:

2173 Salk Avenue, Suite 200, Carlsbad, United States

dannyschell Apr. 8 at 8:07 PM

$LCTX a tad less than 4 weeks till ARVO . We’re not the keynote placement so not expecting much. Ph3 had to happen someday. About the same for the next quarterly report.

0 · Reply

imatisse Apr. 8 at 2:28 PM

$LCTX This is not a steel plant you can “bomb” with macro narratives. This is IP, clinical data, and patented cell therapy platforms. The value here is driven by science, trial outcomes, and partnerships—not geopolitics. Israel exposure = R&D infrastructure, not the business model. If you’re trading headlines, you’re missing the asset.

1 · Reply

qwertylicious2003 Apr. 8 at 2:03 PM

$LCTX

2 · Reply

Forenzi Apr. 8 at 11:01 AM

$LCTX far from a falling knife. More like a slow drift down. In line with microcap biotech which is more volatile than the indexes in risk-off scenarios.

0 · Reply

Migane Apr. 8 at 10:50 AM

$LCTX i would not invest yet until war finish at all. Key assets in israel. Take care lads! Bright future ahead in this company

2 · Reply

kellymone2 Apr. 8 at 10:03 AM

$LCTX one day this stock will be big (or bought)

0 · Reply

DiligentInvesting Apr. 8 at 9:59 AM

$LCTX Up big PM. Might run. Also check $SLS.

1 · Reply

JP73 Apr. 7 at 11:11 PM

$LCTX $USO $NOV Oil futures are down 16% as of now. Trading with a 94 handle.

1 · Reply

qwertylicious2003 Apr. 7 at 2:49 PM

$LCTX $SANA $VRTX https://www.livescience.com/health/a-cure-on-the-horizon-are-we-finally-close-to-ending-type-1-diabetes

0 · Reply

sfoblader Apr. 7 at 1:50 PM

$LCTX I wouldn’t try to catch this falling knife. Macro headwinds are going to push the price to ridiculously undervalued levels. Let it fall and wait for real signs of global stability before adding or wading in.

2 · Reply

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Mar 5, 2026, 4:01 PM EST - 4 weeks ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 8:00 AM EST - 5 weeks ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Jan 6, 2026, 8:00 AM EST - 3 months ago

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Jan 5, 2026, 8:00 AM EST - 3 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

Nov 6, 2025, 4:01 PM EST - 5 months ago

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 8:00 AM EDT - 5 months ago

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Sep 8, 2025, 8:00 AM EDT - 7 months ago

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Aug 26, 2025, 8:00 AM EDT - 8 months ago

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Aug 12, 2025, 4:01 PM EDT - 8 months ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 4, 2025, 8:00 AM EDT - 8 months ago

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Jun 23, 2025, 7:39 AM EDT - 10 months ago

Two Biotech Stocks Poised For Big Moves On Monday

SANA

Jun 23, 2025, 7:00 AM EDT - 10 months ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

May 14, 2025, 8:00 AM EDT - 11 months ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 13, 2025, 4:01 PM EDT - 11 months ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 11 months ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 4, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Jan 27, 2025, 4:05 PM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Nov 21, 2024, 5:00 PM EST - 1 year ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 14, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Sep 25, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 2 years ago

Lineage to Present at 2024 BIO International Convention

May 21, 2024, 8:00 AM EDT - 2 years ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 9, 2024, 4:01 PM EDT - 2 years ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 2 years ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 2, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Apr 29, 2024, 4:30 PM EDT - 2 years ago

Lineage Announces Changes to Board of Directors

Apr 23, 2024, 8:05 AM EDT - 2 years ago

Lineage Announces Appointment of New Board Member

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Mar 13, 2024, 8:00 AM EDT - 2 years ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Mar 11, 2024, 8:00 AM EDT - 2 years ago

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

dannyschell Apr. 8 at 8:07 PM

$LCTX a tad less than 4 weeks till ARVO . We’re not the keynote placement so not expecting much. Ph3 had to happen someday. About the same for the next quarterly report.

0 · Reply

imatisse Apr. 8 at 2:28 PM

1 · Reply

qwertylicious2003 Apr. 8 at 2:03 PM

$LCTX

2 · Reply

Forenzi Apr. 8 at 11:01 AM

$LCTX far from a falling knife. More like a slow drift down. In line with microcap biotech which is more volatile than the indexes in risk-off scenarios.

0 · Reply

Migane Apr. 8 at 10:50 AM

$LCTX i would not invest yet until war finish at all. Key assets in israel. Take care lads! Bright future ahead in this company

2 · Reply

kellymone2 Apr. 8 at 10:03 AM

$LCTX one day this stock will be big (or bought)

0 · Reply

DiligentInvesting Apr. 8 at 9:59 AM

$LCTX Up big PM. Might run. Also check $SLS.

1 · Reply

JP73 Apr. 7 at 11:11 PM

$LCTX $USO $NOV Oil futures are down 16% as of now. Trading with a 94 handle.

1 · Reply

qwertylicious2003 Apr. 7 at 2:49 PM

$LCTX $SANA $VRTX https://www.livescience.com/health/a-cure-on-the-horizon-are-we-finally-close-to-ending-type-1-diabetes

0 · Reply

sfoblader Apr. 7 at 1:50 PM

2 · Reply

Wawawiiwa Apr. 7 at 1:12 PM

$LCTX low 1,40's might buy 10k shares

0 · Reply

DiligentInvesting Apr. 7 at 10:29 AM

$LCTX Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx - CBS News https://share.google/pqwUXlOgbspCPaXks

1 · Reply

ironhide Apr. 6 at 8:37 PM

$LCTX damn, we're really struggling here. Any upcoming catalysts?

1 · Reply

JerryMalone32 Apr. 6 at 5:20 PM

$ELDN $SANA $VCEL $LCTX $AVAI https://www.prnewswire.com/news-releases/why-smart-money-is-shifting-from-clinical-data-to-manufacturing-lines-302734850.html

0 · Reply

TrackRecord24 Apr. 6 at 3:04 PM

$LCTX I too have been optimistic about a potential bump in sp complements of ARVO promotion of four year data...but what motivation for Roche to do that? Roche is absolutely not interested in a jump in sp for $LCTX. Unfortunately, I feel like I'm being held hostage by a timeline I have no control over.

2 · Reply

JohnPDaly Apr. 6 at 12:23 PM

$LCTX Claude:Bottom Line for LCTX OpRegen has a meaningful lead in clinical depth, partner quality, and regulatory signal (RMAT). The GAlette Phase 2a readout — when it comes — will be the pivotal event, as it’s designed to answer the delivery optimization question that Phase 1/2a flagged as important. Astellas is a more capable manufacturing organization than it’s given credit for, but ASP7317 is trailing on data and has a less prominent development partner. The RPE transplant field validating broadly in 2025 is a tailwind for both, but OpRegen is the better-positioned asset right now.

1 · Reply

qwertylicious2003 Apr. 6 at 10:05 AM

$LCTX Take a gander at the competition’s slide deck. Things I notice: - Astellas RPE cell therapy is a FLAGSHIP program in development - Prelim safety and efficacy data presented at ARVO in May 2026 Feels like it would be foolish not to dunk on Astellas at ARVO with some killer Galette data… or at least 4 year ph1 data, no? https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/Investors-Meeting/astellas_rd_day_presentation_20260331_en.pdf

2 · Reply

qwertylicious2003 Apr. 6 at 9:52 AM

$LCTX Let’s go!

3 · Reply

imatisse Apr. 5 at 7:08 AM

$LCTX Hopefully it stays calm in California. « Trump Slashed Science Funding. Now the US Could Face a Costly Brain Drain. The White House's attacks on academia and budget cuts for research have provided an opening for other countries to poach leading »

2 · Reply

SPS614 Apr. 4 at 5:45 PM

$LCTX https://x.com/zachorsomthin/status/2040469145456681392?s=46&t=Blic2Ph7feiddH5StfpqHg

1 · Reply

z06forum Apr. 4 at 10:09 AM

$LCTX interesting chart... Some things in here we have not noticed or talked about..

3 · Reply

AS2021 Apr. 4 at 9:28 AM

$LCTX Is ts-micro a re-branding of the Orbit SDS device? Or is ts-micro the brand name for a different device?

4 · Reply

Market Cap	383.60M
Revenue (ttm)	14.56M
Net Income (ttm)	-63.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-436.33%
Debt to Equity Ratio	0.00

Volume	1,209,800
Avg Vol	1,198,346
Day's Range	N/A - N/A
Shares Out	249.09M
Stochastic %K	39%
Beta	1.79
Analysts	Strong Sell
Price Target	$4.50